OneCell Diagnostics, a genomics-based startup in precision oncology, has raised $16 million in an oversubscribed Series A round to expand its innovative cancer diagnosis technology in the US and India. The startup's proprietary cell biopsy technology helps detect cancer recurrence through circulating tumor cells, providing better diagnosis with at least 100 times more information than current liquid biopsy testing.

The startup's technology has already served nearly 10,000 patients in India and is now looking to replicate its early success in the US. OneCell's in-house blood-based biopsy testing combines circulating tumor cell-DNA with RNA and cell surface protein testing, providing a more accurate diagnosis. The startup has also developed an app called iCare, which works as a precision oncology console to help oncologists interpret test reports using AI and machine learning.

OneCell's goal is to make precision oncology accessible to every oncologist in every hospital globally. With its innovative technology and affordable pricing, one-fifth the cost of competitors, OneCell is poised to revolutionize the cancer diagnosis landscape. The startup plans to reach over 1,000 oncologists and a million patients in the near term, making it a significant player in the healthtech industry.